1. Mateon Therapeutics Mateon Therapeutics United States says:

    Max Planck Institute's data on Artemisinin is in agreement with our previously reported SARS-COV-2 antiviral activity of purified Artemisinin vs. Artemesia extract.  Based on the in vitro data and anectodal clinical data we have launched a global interventional study to evaluate the Artemisinin versus COVID-19.  The drug product was also approved by India's AYUSH ministry.

    investor.mateon.com/.../mateon-announces-first-patient-enrolled-arti-19-multicenter

    investor.mateon.com/.../mateon-therapeutics-initiate-commercialization-artishieldtm

    We encourage collaboration among the various stakeholders to quickly arrive at a cure for COVID-19.

    Regards
    Vuong Trieu PhD
    CEO/Mateon Therapeutics

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.